Rapid Acting Insulin Use and Persistence among Elderly Type 2 Diabetes Patients Adding RAI to Oral Antidiabetes Drug Regimens
We examined the real-world utilization and persistence of rapid acting insulin (RAI) in elderly patients with type 2 diabetes who added RAI to their drug (OAD) regimen. Insulin-naïve patients aged ≥65 years, with ≥1 OAD prescription during the baseline period, who were continuously enrolled in the U...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2016/5374931 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554658660352000 |
|---|---|
| author | Usha Sambamoorthi Arijita Deb Steve Zhou Rahul Garg Tao Fan Anders Boss |
| author_facet | Usha Sambamoorthi Arijita Deb Steve Zhou Rahul Garg Tao Fan Anders Boss |
| author_sort | Usha Sambamoorthi |
| collection | DOAJ |
| description | We examined the real-world utilization and persistence of rapid acting insulin (RAI) in elderly patients with type 2 diabetes who added RAI to their drug (OAD) regimen. Insulin-naïve patients aged ≥65 years, with ≥1 OAD prescription during the baseline period, who were continuously enrolled in the US Humana Medicare Advantage insurance plan for 18 months and initiated RAI were included. Among patients with ≥2 RAI prescriptions (RAIp), persistence during the 12-month follow-up was assessed. Multivariate logistic regression analyses identified factors affecting RAI use and persistence. Of 3734 patients adding RAI to their OAD regimen, 2334 (62.5%) had a RAIp during follow-up. Factors associated with RAIp included using ≤2 OADs; cognitive impairment, basal insulin use during follow-up; and higher RAI out-of-pocket costs ($36 to <$56 versus $0 to $6.30). Patients were less likely to persist with RAI when on ≤2 OADs versus ≥3 OADs and when having higher RAI out-of-pocket costs ($36 to <$56 versus $0 to $6.30) and more likely to persist when they had cognitive impairment and basal insulin use during follow-up. Real-world persistence of RAI in insulin-naïve elderly patients with type 2 diabetes was very poor when RAI was added to an OAD regimen. |
| format | Article |
| id | doaj-art-b94b0823752f4dbbb9b7d6069a608d07 |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-b94b0823752f4dbbb9b7d6069a608d072025-02-03T05:51:00ZengWileyJournal of Diabetes Research2314-67452314-67532016-01-01201610.1155/2016/53749315374931Rapid Acting Insulin Use and Persistence among Elderly Type 2 Diabetes Patients Adding RAI to Oral Antidiabetes Drug RegimensUsha Sambamoorthi0Arijita Deb1Steve Zhou2Rahul Garg3Tao Fan4Anders Boss5School of Pharmacy, West Virginia University, Morgantown, WV, USASchool of Pharmacy, West Virginia University, Morgantown, WV, USASanofi US, Inc., Bridgewater, NJ, USASchool of Pharmacy, West Virginia University, Morgantown, WV, USASanofi US, Inc., Bridgewater, NJ, USASanofi US, Inc., Bridgewater, NJ, USAWe examined the real-world utilization and persistence of rapid acting insulin (RAI) in elderly patients with type 2 diabetes who added RAI to their drug (OAD) regimen. Insulin-naïve patients aged ≥65 years, with ≥1 OAD prescription during the baseline period, who were continuously enrolled in the US Humana Medicare Advantage insurance plan for 18 months and initiated RAI were included. Among patients with ≥2 RAI prescriptions (RAIp), persistence during the 12-month follow-up was assessed. Multivariate logistic regression analyses identified factors affecting RAI use and persistence. Of 3734 patients adding RAI to their OAD regimen, 2334 (62.5%) had a RAIp during follow-up. Factors associated with RAIp included using ≤2 OADs; cognitive impairment, basal insulin use during follow-up; and higher RAI out-of-pocket costs ($36 to <$56 versus $0 to $6.30). Patients were less likely to persist with RAI when on ≤2 OADs versus ≥3 OADs and when having higher RAI out-of-pocket costs ($36 to <$56 versus $0 to $6.30) and more likely to persist when they had cognitive impairment and basal insulin use during follow-up. Real-world persistence of RAI in insulin-naïve elderly patients with type 2 diabetes was very poor when RAI was added to an OAD regimen.http://dx.doi.org/10.1155/2016/5374931 |
| spellingShingle | Usha Sambamoorthi Arijita Deb Steve Zhou Rahul Garg Tao Fan Anders Boss Rapid Acting Insulin Use and Persistence among Elderly Type 2 Diabetes Patients Adding RAI to Oral Antidiabetes Drug Regimens Journal of Diabetes Research |
| title | Rapid Acting Insulin Use and Persistence among Elderly Type 2 Diabetes Patients Adding RAI to Oral Antidiabetes Drug Regimens |
| title_full | Rapid Acting Insulin Use and Persistence among Elderly Type 2 Diabetes Patients Adding RAI to Oral Antidiabetes Drug Regimens |
| title_fullStr | Rapid Acting Insulin Use and Persistence among Elderly Type 2 Diabetes Patients Adding RAI to Oral Antidiabetes Drug Regimens |
| title_full_unstemmed | Rapid Acting Insulin Use and Persistence among Elderly Type 2 Diabetes Patients Adding RAI to Oral Antidiabetes Drug Regimens |
| title_short | Rapid Acting Insulin Use and Persistence among Elderly Type 2 Diabetes Patients Adding RAI to Oral Antidiabetes Drug Regimens |
| title_sort | rapid acting insulin use and persistence among elderly type 2 diabetes patients adding rai to oral antidiabetes drug regimens |
| url | http://dx.doi.org/10.1155/2016/5374931 |
| work_keys_str_mv | AT ushasambamoorthi rapidactinginsulinuseandpersistenceamongelderlytype2diabetespatientsaddingraitooralantidiabetesdrugregimens AT arijitadeb rapidactinginsulinuseandpersistenceamongelderlytype2diabetespatientsaddingraitooralantidiabetesdrugregimens AT stevezhou rapidactinginsulinuseandpersistenceamongelderlytype2diabetespatientsaddingraitooralantidiabetesdrugregimens AT rahulgarg rapidactinginsulinuseandpersistenceamongelderlytype2diabetespatientsaddingraitooralantidiabetesdrugregimens AT taofan rapidactinginsulinuseandpersistenceamongelderlytype2diabetespatientsaddingraitooralantidiabetesdrugregimens AT andersboss rapidactinginsulinuseandpersistenceamongelderlytype2diabetespatientsaddingraitooralantidiabetesdrugregimens |